Unicycive presents on development progress of oxylanthanum carbonate
PremiumThe FlyUnicycive presents on development progress of oxylanthanum carbonate
17d ago
Unicycive Therapeutics completes UNI-494 Phase 1 study
Premium
The Fly
Unicycive Therapeutics completes UNI-494 Phase 1 study
1M ago
Unicycive Therapeutics submits NDA to FDA for oxylanthanum carbonate
Premium
The Fly
Unicycive Therapeutics submits NDA to FDA for oxylanthanum carbonate
2M ago
Unicycive Therapeutics granted patent on UNI-494 from USPTO
PremiumThe FlyUnicycive Therapeutics granted patent on UNI-494 from USPTO
4M ago
Unicycive announces initial results from patient reported outcome survey on OLC
Premium
The Fly
Unicycive announces initial results from patient reported outcome survey on OLC
4M ago
Unicycive Therapeutics initiated with a Buy at Brookline
Premium
The Fly
Unicycive Therapeutics initiated with a Buy at Brookline
4M ago
Unicycive Therapeutics delivers presentations on OLC, UNI-494
PremiumThe FlyUnicycive Therapeutics delivers presentations on OLC, UNI-494
6M ago
Unicycive Therapeutics presents new data on OLC at NKF meeting
Premium
The Fly
Unicycive Therapeutics presents new data on OLC at NKF meeting
6M ago
Unicycive Therapeutics reports Q1 EPS (61c), consensus (15c)
Premium
The Fly
Unicycive Therapeutics reports Q1 EPS (61c), consensus (15c)
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100